Tauriga Sciences Inc. to Construct Product Showroom Within its New Corporate Headquarters
By Dr. Matthew Watson
NEW YORK, NY, Jan. 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as an ongoing Pharmaceutical Development initiative, today announced that it is constructing a Product Showroom (“Showroom”) inside its new corporate headquarters. The Company has made this decision in anticipation of and in preparation for important future Agreement(s) & Partnership(s). The Company expects to host a broad array of prospective new customers, once this Showroom is functional. These potential new customers include, but are not limited to: Individual Customers, Mom & Pop Stores, Gas Station Convenience Stores, Large Regional & National Retailers, Major Distributors, and College Campus Stores.
Read this article:
Tauriga Sciences Inc. to Construct Product Showroom Within its New Corporate Headquarters
- Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference - February 19th, 2021
- Fulcrum Therapeutics to Participate in Upcoming Investor Conferences - February 19th, 2021
- Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference - February 19th, 2021
- Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol... - February 19th, 2021
- Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021 - February 19th, 2021
- BioVie Interview to Air on Bloomberg TV in the US on the RedChip Money Report® - February 19th, 2021
- BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i... - February 19th, 2021
- Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA - February 19th, 2021
- Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updates - February 19th, 2021
- Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform - February 19th, 2021
- Assembly Bio Announces Upcoming Investor Events - February 19th, 2021
- RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference - February 19th, 2021
- Intercept to Present at Upcoming Investor Conferences - February 19th, 2021
- CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology - February 19th, 2021
- Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan - February 19th, 2021
- Yield10 Bioscience Announces Warrant Exercises for Proceeds of $3.8 million - February 19th, 2021
- Information expressed in the public domain by the Repharm Group is deceptive and contradictory - February 19th, 2021
- Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on... - February 19th, 2021
- Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021 - February 19th, 2021
- Ayala Pharmaceuticals Announces $25 Million Strategic Financing - February 19th, 2021
- Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update - February 17th, 2021
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results - February 17th, 2021
- Lumos Pharma Announces Changes to its Board of Directors - February 17th, 2021
- Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference - February 17th, 2021
- Eton Pharmaceuticals to Participate in 10th Annual SVB Leerink Global Healthcare Conference - February 17th, 2021
- Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels - February 17th, 2021
- Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - February 17th, 2021
- Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021 - February 17th, 2021
- MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021 - February 17th, 2021
- Aleafia Health Announces $15 Million Bought Deal Offering of Units - February 17th, 2021
- Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side - February 17th, 2021
- ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome - February 17th, 2021
- Travere Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results - February 17th, 2021
- Wave Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference - February 17th, 2021
- GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference - February 17th, 2021
- ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference - February 17th, 2021
- Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million - February 17th, 2021
- Innate Pharma to Participate in the 10th Annual SVB Leerink Global Healthcare Conference - February 17th, 2021
- Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities... - February 17th, 2021
- Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease - February 17th, 2021
- Vistin Pharma ASA: Invitation to Q4 2020 conference call - February 14th, 2021
- Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine - February 14th, 2021
- Vericel Announces Termination of Shareholder Rights Agreement - February 14th, 2021
- Quotient Limited Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - February 14th, 2021
- Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021 - February 14th, 2021
- Cronos Group Inc. to Hold 2020 Fourth Quarter and Full-Year Earnings Conference Call on February 26, 2021 - February 14th, 2021
- Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day - February 14th, 2021
- Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering - February 14th, 2021
- Delisting of AS „Grindeks” shares from the Baltic Main list - February 14th, 2021
- Trading in Novo Nordisk shares by board members, executives and associated persons on 11-12 February 2021 - February 14th, 2021
- Tauriga Sciences Inc. to Commence Development of its 1st Full Spectrum CBD Infused Edibles Product Line - February 14th, 2021
- New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three... - February 14th, 2021
- Radius Health, Inc. Provides Abaloparatide Business Update - February 14th, 2021
- Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the... - February 14th, 2021
- Tauriga Sciences, Inc. Now Configured to Accept the Following Cryptocurrencies as Payment Options on Its E-Commerce Platform: Bitcoin (BTC), Etherium... - February 14th, 2021
- FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced... - February 14th, 2021
- Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares - February 14th, 2021
- Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx - February 14th, 2021
- Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock - February 14th, 2021
- Neck Hammock Reviews – Does this gadget really help? – Product Review by Mike Vaughn - February 14th, 2021
- Intercept to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 - February 11th, 2021
- Cidara Therapeutics to Present New Data for Rezafungin and Influenza AVCs at the 21st ICHS Symposium - February 11th, 2021
- Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021 - February 11th, 2021
- X4 Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host a Conference Call and Webcast on March 4, 2021 - February 11th, 2021
- VYNE Therapeutics Announces Reverse Stock Split - February 11th, 2021
- BioDelivery Sciences CFO Terry Coelho Promoted to Executive Vice President - February 11th, 2021
- aTyr Pharma Announces New tRNA Synthetase Discovery Programs - February 11th, 2021
- Zogenix to Release Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25 - February 11th, 2021
- electroCore Announces Completion of Enrollment in SAVIOR-1 Study of Non-Invasive Vagus Nerve Stimulation (nVNS) in COVID-19 Patients Exhibiting... - February 11th, 2021
- scPharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference - February 11th, 2021
- Syneos Health Identifies Important Drivers of Change Expected to Disrupt Healthcare - February 11th, 2021
- Albireo Presents Odevixibat Commercialization Road to $1 Billion - February 11th, 2021
- Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg) - February 11th, 2021
- Acer Therapeutics Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions - February 11th, 2021
- Senti Bio to Participate in Upcoming Investor Conferences - February 11th, 2021
- Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space... - February 11th, 2021
- Gain Therapeutics Presents Positive Pre-Clinical Data Supportive of In Vitro Target Engagement for Gaucher Disease, GM1 Gangliosidosis and Morquio B... - February 11th, 2021
- ORYZON Announces FDA Orphan Drug Designation Granted to iadademstat for Treatment of Acute Myeloid Leukemia - February 11th, 2021
- WeedMD Inc. Announces Increase in Bought Deal Equity Financing to $17.5 Million - February 11th, 2021
- Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2020 - February 11th, 2021
